Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Severe COPD

This is a post marketing trial to study the effects of taking Aclidinium Bromide known as Arcapta on COPD patients. It is collecting cardiovascular safety information on subject taking it or a placebo inhaler. Subjects are on study for over 2 years and receive rescue medication free of charge.

Purpose: This study is looking to enroll subjects who have a medical history of cardiac disease and taking Aclidinium and other COPD medications. This purpose of this study is to evaluate cardiac events during the course of the study.

Eligibility: You may be eligible if you are over 40 years of age and are a current or former smoker with a history of at least 10 pack years.

AstraZeneca (Formerly Forest Pharmaceuticals) 
Principal Investigator: Cristine Berry, MD, MHS
Contact Information:
Osmara Y. Molina de Rodriguez, MS
Cell: (520) 891-6767 or Office: (520) 626-3910


Study Status: